1
|
Miyake MM, Valera FCP, Martins RB, Compagnoni IM, Fantucci MZ, Murashima AAB, da Silva LECM, de Lima TM, de Souza MVO, Melo SR, Dolci RLL, Floriano CG, de Campos CAC, Nakanishi M, Freire GSM, Valente AL, Fornazieri MA, da Silva JLB, Anzolin LK, Issa MJA, Souza TV, Lima BA, SantAnna GD, Abreu CB, Sakano E, Cassettari AJ, Avelino MAG, Goncalves MC, de Camargo LA, Romano FR, Alves RD, Roithmann R, Redeker NK, Filho LLB, Dassi CS, Meurer ATO, Garcia DM, Aragon DC, Tepedino MS, Succar ACS, Vianna PM, Dos Santos MCJ, Filho RHR, Kosugi EM, Villa JF, Gregorio LL, Piltcher OB, Meotti CD, Tamashiro E, Arruda E, Anselmo Lima WT. Smell loss associated with SARS-CoV-2 is not clinically different from other viruses: a multicenter cohort study. Rhinology 2024; 62:55-62. [PMID: 37772802 DOI: 10.4193/rhin23.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2023]
Abstract
BACKGROUND Although the COVID-19 pandemic has increased the prevalence of cases with olfactory loss, other respiratory viruses can also cause this condition. We aimed to compare the prevalence of acute SARS-CoV-2 infection and other respiratory viruses in patients with sudden smell loss, and to assess the impact of SARS-CoV-2 viral load and co-infection on olfactory symptoms. METHODS Patients with sudden smell loss were recruited in a multicenter prospective cohort study in 15 hospitals in Brazil. Clinical questionnaire, Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory test and nasopharyngeal swab to perform a PCR-based respiratory viral panel were collected at first visit (day 0) and 30 and 60 days after recruitment. RESULTS 188 of 213 patients presented positive test result for SARS-CoV-2, among which 65 were co-infected with other respiratory viruses (e.g., rhinovirus, enterovirus, and parainfluenza). 25 had negative test results for SARS-CoV-2. Patients in both SARSCoV-2 and non-SARS-CoV-2 groups had objective anosmia (less than 2 points according to the psychophysical olfactory CCCRC) at day 0, with no significant difference between them. Both groups had significant smell scores improvement after 30 and 60 days, with no difference between them. Co-infection with other respiratory viruses, and SARS-CoV-2 viral load did not impact olfactory scores. CONCLUSION Patients with sudden smell loss associated with SARS-CoV-2 and other respiratory viruses had similar presentation, with most participants initiating with anosmia, and total or near total recovery after 60 days. SARS-CoV-2 viral load and co-infections with other respiratory viruses were not associated with poorer olfactory outcomes.
Collapse
Affiliation(s)
- M M Miyake
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil and Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, SP, Brazil
| | - F C P Valera
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - R B Martins
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - I M Compagnoni
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - M Z Fantucci
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - A A B Murashima
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - L E C M da Silva
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - T M de Lima
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - M V O de Souza
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - S R Melo
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - R L L Dolci
- Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, SP, Brazil
| | - C G Floriano
- Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, SP, Brazil
| | - C A C de Campos
- Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, SP, Brazil
| | - M Nakanishi
- University of Brasilia, Brasilia, DF, Brazil
| | | | - A L Valente
- University of Brasilia, Brasilia, DF, Brazil
| | | | | | - L K Anzolin
- State University of Londrina, Londrina, PR, Brazil
| | - M J A Issa
- Mater Dei Hospital, Belo Horizonte, MG, Brazil
| | - T V Souza
- Mater Dei Hospital, Belo Horizonte, MG, Brazil
| | - B A Lima
- Mater Dei Hospital, Belo Horizonte, MG, Brazil
| | - G D SantAnna
- Santa Casa de Misericordia Hospital de Porto Alegre, Porto Alegre, RS, Brazil
| | - C B Abreu
- Santa Casa de Misericordia Hospital de Porto Alegre, Porto Alegre, RS, Brazil
| | - E Sakano
- State University of Campinas. Campinas, SP, Brazil
| | | | | | | | | | | | - R D Alves
- Hospital Moriah, Sao Paulo, SP, Brazil
| | - R Roithmann
- Lutheran University of Brazil, Canoas, RS, Brazil
| | - N K Redeker
- Lutheran University of Brazil, Canoas, RS, Brazil
| | - L L B Filho
- Hospital Edmundo Vasconcelos, Sao Paulo, SP, Brazil
| | - C S Dassi
- Hospital Edmundo Vasconcelos, Sao Paulo, SP, Brazil
| | - A T O Meurer
- Hospital Edmundo Vasconcelos, Sao Paulo, SP, Brazil
| | - D M Garcia
- Ribeirio Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - D C Aragon
- Ribeirio Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - M S Tepedino
- State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - A C S Succar
- State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - P M Vianna
- State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | | | | | - E M Kosugi
- Federal University of Sao Paulo, Sao Paulo, SP, Brazil
| | - J F Villa
- Federal University of Sao Paulo, Sao Paulo, SP, Brazil
| | - L L Gregorio
- Federal University of Sao Paulo, Sao Paulo, SP, Brazil
| | | | - C D Meotti
- Hospital de Clinicas Porto Alegre, RS, Brazil
| | - E Tamashiro
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - E Arruda
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| | - W T Anselmo Lima
- Ribeiro Preto Medical School, University of Sao Paulo, Ribeiro Preto, SP, Brazil
| |
Collapse
|
2
|
Bird O, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove CA, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jeanes C, Kalra PA, Kyriakidou C, Bradley JM, Munthali C, Minassian AM, McGill F, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Heath PT, Chis Ster I. The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight. Epidemiol Infect 2024; 152:e37. [PMID: 38250791 PMCID: PMC10945957 DOI: 10.1017/s0950268824000037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 12/17/2023] [Accepted: 12/27/2023] [Indexed: 01/23/2024] Open
Abstract
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory power for the disease using longitudinally, prospectively collected information reported at the time of their occurrence. We have analysed data from a large phase 3 clinical UK COVID-19 vaccine trial. The alpha variant was the predominant strain. Participants were assessed for SARS-CoV-2 infection via nasal/throat PCR at recruitment, vaccination appointments, and when symptomatic. Statistical techniques were implemented to infer estimates representative of the UK population, accounting for multiple symptomatic episodes associated with one individual. An optimal diagnostic model for SARS-CoV-2 infection was derived. The 4-month prevalence of SARS-CoV-2 was 2.1%; increasing to 19.4% (16.0%-22.7%) in participants reporting loss of appetite and 31.9% (27.1%-36.8%) in those with anosmia/ageusia. The model identified anosmia and/or ageusia, fever, congestion, and cough to be significantly associated with SARS-CoV-2 infection. Symptoms' dynamics were vastly different in the two groups; after a slow start peaking later and lasting longer in PCR+ participants, whilst exhibiting a consistent decline in PCR- participants, with, on average, fewer than 3 days of symptoms reported. Anosmia/ageusia peaked late in confirmed SARS-CoV-2 infection (day 12), indicating a low discrimination power for early disease diagnosis.
Collapse
Affiliation(s)
- Olivia Bird
- Vaccine Institute, St. George’s University of London, St. George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | - Eva P. Galiza
- Vaccine Institute, St. George’s University of London, St. George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
| | - David Neil Baxter
- Medical Education, Stockport National Health Service Foundation Trust, Stepping Hill Hospital, Stockport, United Kingdom
| | - Marta Boffito
- Chelsea and Westminster Hospital, National Health Service Foundation Trust, London, United Kingdom
| | - Duncan Browne
- Faculty of Medicine, Imperial College London, London, United Kingdom
- Endocrinology/Diabetes/General Medicine, Royal Cornwall Hospitals National Health Service Trust, Truro, United Kingdom
| | - Fiona Burns
- Faculty of Population Health Sciences, Institute for Global Health, University College London, and Royal Free London National Health Service Foundation Trust, London, United Kingdom
| | - David R. Chadwick
- Centre for Clinical Infection, South Tees Hospitals National Health Service Foundation Trust, James Cook University Hospital, Middlesbrough, United Kingdom
| | | | - Catherine A. Cosgrove
- Vaccine Institute, St. George’s University of London, St. George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
| | - James Galloway
- Centre for Rheumatic Disease, Kings College London, London, United Kingdom
| | - Anna L. Goodman
- Department of Infectious Diseases, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom
- Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom
| | - Amardeep Heer
- Lakeside Healthcare Research, Lakeside Surgeries Corby, Northants, United Kingdom
| | - Andrew Higham
- Gastrointestinal and Liver Services, University Hospitals of Morecambe Bay National Health Service Foundation Trust, Kendal, United Kingdom
| | - Shalini Iyengar
- Accelerated Enrollment Solutions, Synexus Hexham Dedicated Research Site, Hexham General Hospital, Hexham, United Kingdom
| | - Christopher Jeanes
- Department of Microbiology, Norfolk and Norwich University Hospitals National Health Service Foundation Trust, Norfolk, United Kingdom
| | - Philip A. Kalra
- Nephrology, Salford Royal Hospital, Northern Care Alliance National Health Service Foundation Trust, Salford, United Kingdom
| | - Christina Kyriakidou
- Accelerated Enrollment Solutions, Synexus Midlands Dedicated Research Site, Birmingham, United Kingdom
| | - Judy M. Bradley
- Dentistry and Biomedical Sciences, School of Medicine, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University of Belfast, Belfast, United Kingdom
| | - Chigomezgo Munthali
- Accelerated Enrollment Solutions, Synexus Merseyside Dedicated Research Site, Burlington House, Liverpool, United Kingdom
| | - Angela M. Minassian
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
- Oxford Health National Health Service Foundation Trust, Warneford Hospital, Oxford, United Kingdom
| | - Fiona McGill
- Department of Microbiology, Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom
| | - Patrick Moore
- The Adam Practice, Dorset, United Kingdom
- University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom
| | - Imrozia Munsoor
- Accelerated Enrollment Solutions, Synexus Glasgow Dedicated Research Site, Glasgow, United Kingdom
| | - Helen Nicholls
- Accelerated Enrollment Solutions, Synexus Wales Dedicated Research Site, Cardiff, United Kingdom
| | - Orod Osanlou
- School of Medical Sciences (Pharmacology/Pharmacy), Bangor University, Wales, United Kingdom
- Clinical Pharmacology and Therapeutics/General Internal Medicine, Betsi Cadwaladr University Health Board, Wales, United Kingdom
| | - Jonathan Packham
- Academic Unit of Population and Lifespan Sciences, University of Nottingham, Nottingham, United Kingdom
- Department of Rheumatology, Haywood Hospital, Midlands Partnership National Health Service Foundation Trust, Stafford, United Kingdom
| | - Carol H. Pretswell
- Accelerated Enrollment Solutions, Synexus Lancashire Dedicated Research Site, Matrix Park Buckshaw Village, Chorley, United Kingdom
| | - Alberto San Francisco Ramos
- Vaccine Institute, St. George’s University of London, St. George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
| | - Dinesh Saralaya
- National Institute for Health Research, Patient Recruitment Centre, Bradford Teaching Hospitals National Health Service Foundation Trust, Bradford, United Kingdom
| | - Ray P. Sheridan
- Geriatric Medicine, Royal Devon University Healthcare, Exeter, United Kingdom
| | - Richard Smith
- Department of Nephrology, East Suffolk and North Essex National Health Service Foundation Trust, Colchester, United Kingdom
| | - Roy L. Soiza
- Aberdeen Royal Infirmary and Ageing Clinical and Experimental Research Group, University of Aberdeen, Aberdeen, United Kingdom
| | - Pauline A. Swift
- Renal Services, Epsom and St Helier University Hospitals National Health Service Trust, London, United Kingdom
| | - Emma C. Thomson
- School of Infection & Immunity, Medical Research Council-University of Glasgow Centre for Virus Research, and Queen Elizabeth University Hospital, National Health Service Greater Glasgow & Clyde, Glasgow, United Kingdom
| | - Jeremy Turner
- Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospitals National Health Service Foundation Trust, Norfolk, United Kingdom
| | - Marianne Elizabeth Viljoen
- Accelerated Enrollment Solutions, Synexus Manchester Dedicated Research Site, Kilburn House, Manchester, United Kingdom
| | - Paul T. Heath
- Vaccine Institute, St. George’s University of London, St. George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
| | - Irina Chis Ster
- Institute of Infection and Immunity, George’s University of London, London, United Kingdom
| |
Collapse
|
3
|
Thi Khanh HN, Cornelissen L, Castanares-Zapatero D, De Pauw R, Van Cauteren D, Demarest S, Drieskens S, Devleesschauwer B, De Ridder K, Charafeddine R, Smith P. Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population. BMC Infect Dis 2023; 23:774. [PMID: 37940843 PMCID: PMC10634063 DOI: 10.1186/s12879-023-08787-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Accepted: 11/04/2023] [Indexed: 11/10/2023] Open
Abstract
BACKGROUND While many studies on the determinants of post-COVID-19 conditions (PCC) have been conducted, little is known about the relationship between SARS-CoV-2 variants and PCC. This study aimed to assess the association between different SARS-CoV-2 variants and the probability of having PCC three months after the infection. METHODS This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression. RESULTS The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR = 1.61, 95% confidence interval [CI] = 1.33-1.96 and OR = 1.73, 95%CI = 1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC. CONCLUSIONS People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.
Collapse
Affiliation(s)
- Huyen Nguyen Thi Khanh
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium.
- Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
| | - Laura Cornelissen
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
| | | | - Robby De Pauw
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
- Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium
| | | | - Stefaan Demarest
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
| | - Sabine Drieskens
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
| | - Brecht Devleesschauwer
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
- Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium
| | - Karin De Ridder
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
| | - Rana Charafeddine
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
| | - Pierre Smith
- Department of Epidemiology and public health, Sciensano, Brussels, Belgium
- Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
4
|
Faviez C, Talmatkadi M, Foulquié P, Mebarki A, Schück S, Burgun A, Chen X. Assessment of the Early Detection of Anosmia and Ageusia Symptoms in COVID-19 on Twitter: Retrospective Study. JMIR Infodemiology 2023; 3:e41863. [PMID: 37643302 PMCID: PMC10521907 DOI: 10.2196/41863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 06/29/2023] [Accepted: 08/01/2023] [Indexed: 08/31/2023]
Abstract
BACKGROUND During the unprecedented COVID-19 pandemic, social media has been extensively used to amplify the spread of information and to express personal health-related experiences regarding symptoms, including anosmia and ageusia, 2 symptoms that have been reported later than other symptoms. OBJECTIVE Our objective is to investigate to what extent Twitter users reported anosmia and ageusia symptoms in their tweets and if they connected them to COVID-19, to evaluate whether these symptoms could have been identified as COVID-19 symptoms earlier using Twitter rather than the official notice. METHODS We collected French tweets posted between January 1, 2020, and March 31, 2020, containing anosmia- or ageusia-related keywords. Symptoms were detected using fuzzy matching. The analysis consisted of 3 parts. First, we compared the coverage of anosmia and ageusia symptoms in Twitter and in traditional media to determine if the association between COVID-19 and anosmia or ageusia could have been identified earlier through Twitter. Second, we conducted a manual analysis of anosmia- and ageusia-related tweets to obtain quantitative and qualitative insights regarding their nature and to assess when the first associations between COVID-19 and these symptoms were established. We randomly annotated tweets from 2 periods: the early stage and the rapid spread stage of the epidemic. For each tweet, each symptom was annotated regarding 3 modalities: symptom (yes or no), associated with COVID-19 (yes, no, or unknown), and whether it was experienced by someone (yes, no, or unknown). Third, to evaluate if there was a global increase of tweets mentioning anosmia or ageusia in early 2020, corresponding to the beginning of the COVID-19 epidemic, we compared the tweets reporting experienced anosmia or ageusia between the first periods of 2019 and 2020. RESULTS In total, 832 (respectively 12,544) tweets containing anosmia (respectively ageusia) related keywords were extracted over the analysis period in 2020. The comparison to traditional media showed a strong correlation without any lag, which suggests an important reactivity of Twitter but no earlier detection on Twitter. The annotation of tweets from 2020 showed that tweets correlating anosmia or ageusia with COVID-19 could be found a few days before the official announcement. However, no association could be found during the first stage of the pandemic. Information about the temporality of symptoms and the psychological impact of these symptoms could be found in the tweets. The comparison between early 2020 and early 2019 showed no difference regarding the volumes of tweets. CONCLUSIONS Based on our analysis of French tweets, associations between COVID-19 and anosmia or ageusia by web users could have been found on Twitter just a few days before the official announcement but not during the early stage of the pandemic. Patients share qualitative information on Twitter regarding anosmia or ageusia symptoms that could be of interest for future analyses.
Collapse
Affiliation(s)
- Carole Faviez
- Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1138, Paris, France
- Health Data- and Model- Driven Knowledge Acquisition (HeKA), Inria Paris, Paris, France
| | | | | | | | | | - Anita Burgun
- Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1138, Paris, France
- Health Data- and Model- Driven Knowledge Acquisition (HeKA), Inria Paris, Paris, France
- Department of Medical Informatics, Hôpital Necker-Enfant Malades, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Xiaoyi Chen
- Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1138, Paris, France
- Health Data- and Model- Driven Knowledge Acquisition (HeKA), Inria Paris, Paris, France
- Data Science Platform, Imagine Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Paris, France
| |
Collapse
|
5
|
Tajer C, Martínez MJ, Mariani J, De Abreu M, Antonietti L. Post COVID-19 syndrome. Severity and evolution in 4673 health care workers. Medicina (B Aires) 2023; 83:669-682. [PMID: 37870325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2023] Open
Abstract
BACKGROUND The evolution of post COVID syndrome has been variable and we lack information on its impact on healthcare professionals, particularly in Latin America. METHODS We conducted a survey through a social network in health professionals on post COVID-19 syndrome cases confirmed with PCR. In a web-based questionnaire, we asked about 21 symptoms, their severity, duration, degree of activity impairment and return to work. RESULTS 4673 health professionals from 21 countries responded, mean age of 47.8 years, 64.2% women. The initial course was asymptomatic in 9.1%, mild symptoms 36.8%, moderate symptoms without hospitalization 40.8% or with hospitalization 11.7%, and severe symptoms with respiratory assistance 1.6%. The most prevalent symptoms were fatigue (67%), insomnia (44.2%), anxiety (42.3%), myalgia (41.9%) and anosmia (41.2%). Considering only severe symptoms (grades 3-4 on a subjective index from 1 to 4), the most prevalent were slowness (36.3%), impaired concentration (33.1%), anosmia (20.4%), fatigue (19.1%), impaired memory (18.1%) and dyspnea (15.9%). Prevalence dropped by half in the first 5 five months, but in many cases, it lasted for more than a year. In the multivariate analysis, symptoms tended to be grouped into clusters (cognitive, neuropsychiatric, cardiorespiratory, digestive, others). The need to change the work area was 16% and lack of return to work 7.8%, related to older age, number of symptoms and severity of the initial course. CONCLUSION In conclusion, in many cases the persistence of post-COVID symptoms can be prolonged and have an occupational impact on healthcare professionals, requiring the adoption of specific policies to reduce harm.
Collapse
Affiliation(s)
- Carlos Tajer
- Departamento de Cardiología, Hospital de Alta Complejidad Néstor Carlos Kirchner, Florencio Varela, Provincia de Buenos Aires, Argentina. E-mail:
| | - María José Martínez
- Departamento de Cardiología, Hospital de Alta Complejidad Néstor Carlos Kirchner, Florencio Varela, Provincia de Buenos Aires, Argentina
| | - Javier Mariani
- Departamento de Cardiología, Hospital de Alta Complejidad Néstor Carlos Kirchner, Florencio Varela, Provincia de Buenos Aires, Argentina
| | - Maximiliano De Abreu
- Departamento de Cardiología, Hospital de Alta Complejidad Néstor Carlos Kirchner, Florencio Varela, Provincia de Buenos Aires, Argentina
| | - Laura Antonietti
- Departamento de Investigación, Universidad Arturo Jauretche, Florencio Varela, Provincia de Buenos Aires, Argentina
| |
Collapse
|
6
|
Bukhari AF, Malas M, Hanbazazah K, Zawawi F. The incidence and impact of anosmia on daily life after COVID-19 infection: A cross-sectional study in a tertiary center in Saudi Arabia. Saudi Med J 2022; 43:1354-1362. [PMID: 36517057 PMCID: PMC9994517 DOI: 10.15537/smj.2022.43.12.20220559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Accepted: 11/08/2022] [Indexed: 12/17/2023] Open
Abstract
OBJECTIVES To investigate the impact of olfactory dysfunction's (OD) on patients with coronavirus disease-19 (COVID-19) and evaluate the risk factors associated with it. METHODS This cross-sectional study analyzed patients who tested positive for COVID-19 over a period of 4 months (May-July 2020) and experienced OD and mild illness. Selected patients were given 2 scales Olfactory Disorders Negative Statement (QOD-NS) and Sino-nasal Outcome Test (SNOT-22). RESULTS A total of 256 patients were enrolled, out of which 196 had anosmia after COVID-19 infection. More than 75% of the participants were aged between 20-40 years and 64.3% were women. The mean score of the patients was 25.13 (SD 19.6) on the SNOT-22, while it was 4.9 (SD 4.85) on the QOD-NS. There was no association between anosmia and other comorbidities and factors (age, smoking history, allergic rhinitis history, asthma, and so on). Only 39% of patients who had anosmia after COVID-19 recovered in less than 4 months. CONCLUSION Olfactory dysfunction is a common symptom of COVID-19 infection and it can take more than 4 months to recover. Nevertheless, this cohort reports a moderate impact on their quality of life due to anosmia.
Collapse
Affiliation(s)
- Afnan F. Bukhari
- From the Department of Otolaryngology-Head and Neck Surgery (Bukhari, Malas, Hanbazazah, Zawawi), King Abdulaziz University, and from the Department of Otolaryngology and Surgery (Malas), King Khaled Hospital, Ministry of National Guard, Jeddah, Kingdom of Saudi Arabia.
| | - Moayyad Malas
- From the Department of Otolaryngology-Head and Neck Surgery (Bukhari, Malas, Hanbazazah, Zawawi), King Abdulaziz University, and from the Department of Otolaryngology and Surgery (Malas), King Khaled Hospital, Ministry of National Guard, Jeddah, Kingdom of Saudi Arabia.
| | - Kamal Hanbazazah
- From the Department of Otolaryngology-Head and Neck Surgery (Bukhari, Malas, Hanbazazah, Zawawi), King Abdulaziz University, and from the Department of Otolaryngology and Surgery (Malas), King Khaled Hospital, Ministry of National Guard, Jeddah, Kingdom of Saudi Arabia.
| | - Faisal Zawawi
- From the Department of Otolaryngology-Head and Neck Surgery (Bukhari, Malas, Hanbazazah, Zawawi), King Abdulaziz University, and from the Department of Otolaryngology and Surgery (Malas), King Khaled Hospital, Ministry of National Guard, Jeddah, Kingdom of Saudi Arabia.
| |
Collapse
|
7
|
Mercier J, Osman M, Bouiller K, Tipirdamaz C, Gendrin V, Chirouze C, Lepiller Q, Bouvier E, Royer P, Pierron A, Toko L, Plantin J, Kadiane‐Oussou N, Zayet S, Klopfenstein T. Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study. J Med Virol 2022; 94:4762-4775. [PMID: 35672249 PMCID: PMC9347548 DOI: 10.1002/jmv.27918] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 03/15/2022] [Accepted: 06/05/2022] [Indexed: 12/15/2022]
Abstract
Olfactory disorders (OD) pathogenesis, underlying conditions, and prognostic in coronavirus disease 2019 (COVID-19) remain partially described. ANOSVID is a retrospective study in Nord Franche-Comté Hospital (France) that included COVID-19 patients from March 1 2020 to May 31 2020. The aim was to compare COVID-19 patients with OD (OD group) and patients without OD (no-OD group). A second analysis compared patients with anosmia (high OD group) and patients with hyposmia or no OD (low or no-OD group). The OD group presented less cardiovascular and other respiratory diseases compared to the no-OD group (odds ratio [OR] = 0.536 [0.293-0.981], p = 0.041 and OR = 0.222 [0.056-0.874], p = 0.037 respectively). Moreover, history of malignancy was less present in the high OD group compared with the low or no-OD group (OR = 0.170 [0.064-0.455], p < 0.001). The main associated symptoms (OR > 5) with OD were loss of taste (OR = 24.059 [13.474-42.959], p = 0.000) and cacosmia (OR = 5.821 [2.246-15.085], p < 0.001). Most of all ORs decreased in the second analysis, especially for general, digestive, and ENT symptoms. Only two ORs increased: headache (OR = 2.697 [1.746-4.167], p < 0.001) and facial pain (OR = 2.901 [1.441-5.842], p = 0.002). The high OD group had a higher creatinine clearance CKD than the low or no-OD group (89.0 ± 21.1 vs. 81.0 ± 20.5, p = 0.040). No significant difference was found concerning the virological, radiological, and severity criteria. OD patients seem to have less comorbidity, especially better cardiovascular and renal function. Associated symptoms with OD were mostly neurological symptoms. We did not find a significant relationship between OD and less severity in COVID-19 possibly due to methodological bias.
Collapse
Affiliation(s)
- Julien Mercier
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Molka Osman
- Faculty of Medicine of TunisUniversity Tunis El ManarTunisTunisia
| | - Kevin Bouiller
- Department of Infectious DiseaseUniversity Hospital of BesançonBesançonFrance
| | - Can Tipirdamaz
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Vincent Gendrin
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Catherine Chirouze
- Department of Infectious DiseaseUniversity Hospital of BesançonBesançonFrance
| | - Quentin Lepiller
- Department of VirologyUniversity Hospital of BesançonBesançonFrance
| | - Elodie Bouvier
- Clinical Research Unit, Nord Franche‐Comté HospitalTrévenansFrance
| | - Pierre‐Yves Royer
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Alix Pierron
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Lynda Toko
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | - Julie Plantin
- Department of MicrobiologyNord Franche‐Comté HospitalTrévenansFrance
| | | | - Souheil Zayet
- Department of Infectious DiseaseNord Franche‐Comté HospitalTrévenansFrance
| | | |
Collapse
|
8
|
Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, Vieira Hennemann Koury G, de Jesus Sousa E, Cerasi AJ, Souza GS, Simões Quaresma JA, Magno Falcão LF. Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction. JAMA Netw Open 2022; 5:e2230637. [PMID: 36074464 PMCID: PMC9459661 DOI: 10.1001/jamanetworkopen.2022.30637] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
IMPORTANCE Determining the characteristics, type, and severity of olfactory dysfunction in patients with long COVID is important for the prognosis and potential treatment of the affected population. OBJECTIVE To describe the sociodemographic and clinical features of patients with long COVID who develop persistent olfactory dysfunction. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study, conducted at a rehabilitation center at a public university in the Amazon region of Brazil between September 9, 2020, and October 20, 2021, comprised 219 patients with long COVID and self-reported neurologic symptoms. Of these 219 patients, 139 received a diagnosis of chronic olfactory dysfunction, as confirmed by the Connecticut Chemosensory Clinical Research Center (CCCRC) test. EXPOSURE Clinical diagnosis of long COVID. MAIN OUTCOMES AND MEASURES Electronic case report forms were prepared for the collection of sociodemographic and clinical data. Patients' sense of smell was evaluated via a CCCRC test, and the association of olfactory dysfunction with aspects of daily life was recorded using a questionnaire. RESULTS Of the 219 patients included in the study, 164 (74.9%) were women, 194 (88.6%) were between 18 and 59 years of age (mean [SD] age, 43.2 [12.9] years), 206 (94.1%) had more than 9 years of education, and 115 (52.5%) had a monthly income of up to US $192.00. In the study group, 139 patients (63.5%) had some degree of olfactory dysfunction, whereas 80 patients (36.5%) had normosmia. Patients with olfactory dysfunction had a significantly longer duration of long COVID symptoms than those in the normosmia group (mean [SD], 242.7 [101.9] vs 221.0 [97.5] days; P = .01). Among patients with anosmia, there was a significant association between olfactory dysfunction and daily activities, especially in terms of impairment in hazard detection (21 of 31 patients [67.7%]), personal hygiene (21 of 31 patients [67.7%]), and food intake (21 of 31 patients [67.7%]). Univariable logistic regression analyses found that ageusia symptoms were associated with the occurrence of olfactory dysfunction (odds ratio [OR], 11.14 [95% CI, 4.76-26.07]; P < .001), whereas headache (OR, 0.41 [95% CI, 0.22-0.76]; P < .001) and sleep disorders (OR, 0.48 [95% CI, 0.26-0.92]; P = .02) showed an inverse association with the occurrence of olfactory dysfunction. CONCLUSIONS AND RELEVANCE Olfactory dysfunction is one of the most important long-term neurologic symptoms of COVID-19, with the highest prevalence seen among women, adults, and outpatients. Patients with olfactory dysfunction may experience persistent severe hyposmia or anosmia more than 1 year from the onset of symptoms, suggesting the possibility of the condition becoming a permanent sequela.
Collapse
Affiliation(s)
- Alna Carolina Mendes Paranhos
- Tropical Medicine Center, Federal University of Pará, Belém, Brazil
- Biological and Health Center, Pará State University, Belém, Brazil
| | | | | | | | | | - Antônio José Cerasi
- Biological Science Center, Federal University of Pará, Belém, Brazil
- Cosmopolita College, Belém, Brazil
| | - Givago Silva Souza
- Tropical Medicine Center, Federal University of Pará, Belém, Brazil
- Biological Science Center, Federal University of Pará, Belém, Brazil
| | - Juarez Antônio Simões Quaresma
- Tropical Medicine Center, Federal University of Pará, Belém, Brazil
- Biological and Health Center, Pará State University, Belém, Brazil
| | - Luiz Fábio Magno Falcão
- Biological and Health Center, Pará State University, Belém, Brazil
- University of São Paulo, São Paulo, Brazil
| |
Collapse
|
9
|
Ganesh A, Reis IR, Varma M, Patry DG, Cooke LJ. Neurological and Head/Eyes/Ears/Nose/Throat Manifestations of COVID-19: A Systematic Review and Meta-Analysis. Can J Neurol Sci 2022; 49:514-531. [PMID: 34287109 PMCID: PMC8460425 DOI: 10.1017/cjn.2021.180] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 07/10/2021] [Accepted: 07/15/2021] [Indexed: 12/18/2022]
Abstract
BACKGROUND/OBJECTIVE Coronavirus disease 2019 (COVID-19) has been associated with various neurological and atypical head/eyes/ears/nose/throat (HEENT) manifestations. We sought to review the evidence for these manifestations. METHODS In this systematic review and meta-analysis, we compiled studies published until March 31, 2021 that examined non-respiratory HEENT, central, and peripheral nervous system presentations in COVID-19 patients. We included 477 studies for qualitative synthesis and 59 studies for meta-analyses. RESULTS Anosmia, ageusia, and conjunctivitis may precede typical upper/lower respiratory symptoms. Central nervous system (CNS) manifestations include stroke and encephalopathy, potentially with brainstem or cranial nerve involvement. MRI studies support CNS para-/postinfectious etiologies, but direct neuroinvasion seems very rare, with few cases detecting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the CNS. Peripheral nervous system (PNS) manifestations include muscle damage, Guillain-Barre syndrome (GBS), and its variants. There was moderate-to-high study heterogeneity and risk of bias. In random-effects meta-analyses, anosmia/ageusia was estimated to occur in 56% of COVID-19 patients (95% CI: 0.41-0.71, I2:99.9%), more commonly than in patients without COVID-19 (OR: 14.28, 95% CI: 8.39-24.29, I2: 49.0%). Neurological symptoms were estimated to occur in 36% of hospitalized patients (95% CI: 0.31-0.42, I2: 99.8%); ischemic stroke in 3% (95% CI: 0.03-0.04, I2: 99.2%), and GBS in 0.04% (0.033%-0.047%), more commonly than in patients without COVID-19 (OR[stroke]: 2.53, 95% CI: 1.16-5.50, I2: 76.4%; OR[GBS]: 3.43,1.15-10.25, I2: 89.1%). CONCLUSIONS Current evidence is mostly from retrospective cohorts or series, largely in hospitalized or critically ill patients, not representative of typical community-dwelling patients. There remains a paucity of systematically gathered prospective data on neurological manifestations. Nevertheless, these findings support a high index of suspicion to identify HEENT/neurological presentations in patients with known COVID-19, and to test for COVID-19 in patients with such presentations at risk of infection.
Collapse
Affiliation(s)
- Aravind Ganesh
- Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Isabella R. Reis
- Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
| | - Malavika Varma
- Department of Emergency Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - David G. Patry
- Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| | - Lara J. Cooke
- Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
| |
Collapse
|
10
|
Elvan-Tuz A, Karadag-Oncel E, Kiran S, Kanik-Yuksek S, Gulhan B, Hacimustafaoglu M, Ozdem-Alatas S, Kuyucu N, Ozdemir H, Egil O, Elmas-Bozdemir S, Polat M, Bursal-Duramaz B, Cem E, Apaydin G, Teksam O. Prevalence of Anosmia in 10.157 Pediatric COVID-19 Cases: Multicenter Study from Turkey. Pediatr Infect Dis J 2022; 41:473-477. [PMID: 35349499 PMCID: PMC9083317 DOI: 10.1097/inf.0000000000003526] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/24/2022] [Indexed: 01/05/2023]
Abstract
INTRODUCTION COVID-19-related anosmia is a remarkable and disease-specific finding. With this multicenter cohort study, we aimed to determine the prevalence of anosmia in pediatric cases with COVID-19 from Turkey and make an objective assessment with a smell awareness questionnaire. MATERIAL AND METHODS This multicenter prospective cohort study was conducted with pediatric infection clinics in 37 centers in 19 different cities of Turkey between October 2020 and March 2021. The symptoms of 10.157 COVID-19 cases 10-18 years old were examined. Age, gender, other accompanying symptoms, and clinical severity of the disease of cases with anosmia and ageusia included in the study were recorded. The cases were interviewed for the smell awareness questionnaire at admission and one month after the illness. RESULTS Anosmia was present in 12.5% (1.266/10.157) of COVID-19 cases 10-18 years of age. The complete records of 1053 patients followed during the study period were analyzed. The most common symptoms accompanying symptoms with anosmia were ageusia in 885 (84%) cases, fatigue in 534 cases (50.7%), and cough in 466 cases (44.3%). Anosmia was recorded as the only symptom in 84 (8%) of the cases. One month later, it was determined that anosmia persisted in 88 (8.4%) cases. In the smell awareness questionnaire, the score at admission was higher than the score one month later (P < 0.001). DISCUSSION With this study, we have provided the examination of a large case series across Turkey. Anosmia and ageusia are specific symptoms seen in cases of COVID-19. With the detection of these symptoms, it should be aimed to isolate COVID-19 cases in the early period and reduce the spread of the infection. Such studies are important because the course of COVID-19 in children differs from adults and there is limited data on the prevalence of anosmia.
Collapse
Affiliation(s)
- Aysegul Elvan-Tuz
- From the Health Sciences University Tepecik Training and Research Hospital, Izmir, Turkey
| | - Eda Karadag-Oncel
- From the Health Sciences University Tepecik Training and Research Hospital, Izmir, Turkey
| | - Sibel Kiran
- Hacettepe University Hospital, Ankara, Turkey
| | | | | | | | | | | | | | - Oguz Egil
- Gaziantep CG Obstetrics and Children’s Hospital, Gaziantep, Turkey
| | | | - Meltem Polat
- Health Sciences University Dr Sami Ulus Training and Research Hospital, Ankara, Turkey
| | | | - Ela Cem
- Health Sciences University Behcet Uz Training and Research Hospital, Izmir, Turkey
| | | | | |
Collapse
|
11
|
Melms L, Falk E, Schieffer B, Jerrentrup A, Wagner U, Matrood S, Schaefer JR, Müller T, Hirsch M. Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic. PLoS One 2021; 16:e0258649. [PMID: 34807925 PMCID: PMC8608328 DOI: 10.1371/journal.pone.0258649] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 10/02/2021] [Indexed: 12/24/2022] Open
Abstract
Pandemic scenarios like SARS-Cov-2 require rapid information aggregation. In the age of eHealth and data-driven medicine, publicly available symptom tracking tools offer efficient and scalable means of collecting and analyzing large amounts of data. As a result, information gains can be communicated to front-line providers. We have developed such an application in less than a month and reached more than 500 thousand users within 48 hours. The dataset contains information on basic epidemiological parameters, symptoms, risk factors and details on previous exposure to a COVID-19 patient. Exploratory Data Analysis revealed different symptoms reported by users with confirmed contacts vs. no confirmed contacts. The symptom combination of anosmia, cough and fatigue was the most important feature to differentiate the groups, while single symptoms such as anosmia, cough or fatigue alone were not sufficient. A linear regression model from the literature using the same symptom combination as features was applied on all data. Predictions matched the regional distribution of confirmed cases closely across Germany, while also indicating that the number of cases in northern federal states might be higher than officially reported. In conclusion, we report that symptom combinations anosmia, fatigue and cough are most likely to indicate an acute SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Leander Melms
- Institute of Artificial Intelligence, Philipps-University Marburg, Marburg, Germany
| | - Evelyn Falk
- Institute of Artificial Intelligence, Philipps-University Marburg, Marburg, Germany
| | - Bernhard Schieffer
- Cardiology Department, University Hospital Gießen and Marburg, Marburg, Germany
| | - Andreas Jerrentrup
- Emergency Department, University Hospital Gießen and Marburg, Marburg, Germany
- Centre for Undiagnosed and Rare Diseases, University Hospital Gießen and Marburg, Marburg, Germany
| | - Uwe Wagner
- Department of Gynaecology, University Hospital Gießen and Marburg, Marburg, Germany
| | - Sami Matrood
- Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, Philipps-University, Marburg, Germany
| | - Jürgen R. Schaefer
- Centre for Undiagnosed and Rare Diseases, University Hospital Gießen and Marburg, Marburg, Germany
| | - Tobias Müller
- Centre for Undiagnosed and Rare Diseases, University Hospital Gießen and Marburg, Marburg, Germany
| | - Martin Hirsch
- Institute of Artificial Intelligence, Philipps-University Marburg, Marburg, Germany
| |
Collapse
|
12
|
Sudre CH, Keshet A, Graham MS, Joshi AD, Shilo S, Rossman H, Murray B, Molteni E, Klaser K, Canas LD, Antonelli M, Nguyen LH, Drew DA, Modat M, Pujol JC, Ganesh S, Wolf J, Meir T, Chan AT, Steves CJ, Spector TD, Brownstein JS, Segal E, Ourselin S, Astley CM. Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study. Lancet Digit Health 2021; 3:e577-e586. [PMID: 34305035 PMCID: PMC8297994 DOI: 10.1016/s2589-7500(21)00115-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 05/05/2021] [Accepted: 06/04/2021] [Indexed: 12/20/2022]
Abstract
BACKGROUND Multiple voluntary surveillance platforms were developed across the world in response to the COVID-19 pandemic, providing a real-time understanding of population-based COVID-19 epidemiology. During this time, testing criteria broadened and health-care policies matured. We aimed to test whether there were consistent associations of symptoms with SARS-CoV-2 test status across three surveillance platforms in three countries (two platforms per country), during periods of testing and policy changes. METHODS For this observational study, we used data of observations from three volunteer COVID-19 digital surveillance platforms (Carnegie Mellon University and University of Maryland Facebook COVID-19 Symptom Survey, ZOE COVID Symptom Study app, and the Corona Israel study) targeting communities in three countries (Israel, the UK, and the USA; two platforms per country). The study population included adult respondents (age 18-100 years at baseline) who were not health-care workers. We did logistic regression of self-reported symptoms on self-reported SARS-CoV-2 test status (positive or negative), adjusted for age and sex, in each of the study cohorts. We compared odds ratios (ORs) across platforms and countries, and we did meta-analyses assuming a random effects model. We also evaluated testing policy changes, COVID-19 incidence, and time scales of duration of symptoms and symptom-to-test time. FINDINGS Between April 1 and July 31, 2020, 514 459 tests from over 10 million respondents were recorded in the six surveillance platform datasets. Anosmia-ageusia was the strongest, most consistent symptom associated with a positive COVID-19 test (robust aggregated rank one, meta-analysed random effects OR 16·96, 95% CI 13·13-21·92). Fever (rank two, 6·45, 4·25-9·81), shortness of breath (rank three, 4·69, 3·14-7·01), and cough (rank four, 4·29, 3·13-5·88) were also highly associated with test positivity. The association of symptoms with test status varied by duration of illness, timing of the test, and broader test criteria, as well as over time, by country, and by platform. INTERPRETATION The strong association of anosmia-ageusia with self-reported positive SARS-CoV-2 test was consistently observed, supporting its validity as a reliable COVID-19 signal, regardless of the participatory surveillance platform, country, phase of illness, or testing policy. These findings show that associations between COVID-19 symptoms and test positivity ranked similarly in a wide range of scenarios. Anosmia, fever, and respiratory symptoms consistently had the strongest effect estimates and were the most appropriate empirical signals for symptom-based public health surveillance in areas with insufficient testing or benchmarking capacity. Collaborative syndromic surveillance could enhance real-time epidemiological investigations and public health utility globally. FUNDING National Institutes of Health, National Institute for Health Research, Alzheimer's Society, Wellcome Trust, and Massachusetts Consortium on Pathogen Readiness.
Collapse
Affiliation(s)
- Carole H Sudre
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Medical Research Council Unit for Lifelong health and Ageing at UCL, Department of Population Science and Experimental Medicine, University College London, London, UK; Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.
| | - Ayya Keshet
- Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Mark S Graham
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Amit D Joshi
- Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Smadar Shilo
- Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Pediatric Diabetes Unit, Ruth Rappaport Children's Hospital, Rambam Healthcare Campus, Haifa, Israel
| | - Hagai Rossman
- Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Benjamin Murray
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Erika Molteni
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Kerstin Klaser
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Liane D Canas
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Michela Antonelli
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Long H Nguyen
- Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - David A Drew
- Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Marc Modat
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | | | | | | | - Tomer Meir
- Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Andrew T Chan
- Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Claire J Steves
- Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
| | - Tim D Spector
- Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; ZOE Global, London, UK
| | - John S Brownstein
- Computational Epidemiology Lab, Boston Children's Hospital, Boston, MA, USA
| | - Eran Segal
- Department of Computer Science and Applied Mathematics and Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Sebastien Ourselin
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; AI Institute 3IA Côte d'Azur, Université Côte d'Azur, Nice, France
| | - Christina M Astley
- Computational Epidemiology Lab, Boston Children's Hospital, Boston, MA, USA; Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| |
Collapse
|
13
|
Abstract
A central problem in the COVID-19 pandemic is that there is not enough testing to prevent infectious spread of SARS-CoV-2, causing surges and lockdowns with human and economic toll. Molecular tests that detect viral RNAs or antigens will be unable to rise to this challenge unless testing capacity increases by at least an order of magnitude while decreasing turnaround times. Here, we evaluate an alternative strategy based on the monitoring of olfactory dysfunction, a symptom identified in 76-83% of SARS-CoV-2 infections-including those with no other symptoms-when a standardized olfaction test is used. We model how screening for olfactory dysfunction, with reflexive molecular tests, could be beneficial in reducing community spread of SARS-CoV-2 by varying testing frequency and the prevalence, duration, and onset time of olfactory dysfunction. We find that monitoring olfactory dysfunction could reduce spread via regular screening, and could reduce risk when used at point-of-entry for single-day events. In light of these estimated impacts, and because olfactory tests can be mass produced at low cost and self-administered, we suggest that screening for olfactory dysfunction could be a high impact and cost-effective method for broad COVID-19 screening and surveillance.
Collapse
Affiliation(s)
- Daniel B Larremore
- Department of Computer Science, University of Colorado Boulder, Boulder, CO, USA.
- BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
| | - Derek Toomre
- Department of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.
| | - Roy Parker
- BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
- Department of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
- Howard Hughes Medical Institute, Chevy Chase, MD, USA.
| |
Collapse
|
14
|
Sheng MZ, Fang TC, Chen YH, Chang MH, Yang CP, Lin CH. Is either anosmia or constipation associated with cognitive dysfunction in Parkinson's disease? PLoS One 2021; 16:e0252451. [PMID: 34086764 PMCID: PMC8177408 DOI: 10.1371/journal.pone.0252451] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 05/14/2021] [Indexed: 11/21/2022] Open
Abstract
Objective To clarify the association of anosmia or constipation with cognitive dysfunction and disease severity in patients with Parkinson’s disease (PD). Methods Newly diagnosed patients with PD (less than 5 years) without a clinical diagnosis of dementia were included from February 2017 to August 2018. The subjects were further divided into subgroups based on whether anosmia occurred and the grade of constipation. The severity of PD motor symptoms was rated using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), and cognitive functions were evaluated by Montreal Cognitive Assessment (MoCA). Statistical analyses including t-tests, chi-square tests, multiple linear regression, and binary logistic regression were used to determine statistical significance. Results A total of 107 newly diagnosed PD patients were included in this study. The MoCA score was significantly lower in the anosmia group (p < 0.001). Constipation was associated with impaired olfaction in a post-hoc test. The correlation coefficient between MoCA and UPSIT score was 0.41 (p < 0.001). Total anosmia and age were associated with cognitive dysfunction (MoCA < 26) (odds ratio, 2.63, p = 0.003; 1.10, p < 0.001, respectively). The anosmia group had a higher MDS-UPDRS part 3 score with β coefficient of 7.30 (p = 0.02). Furthermore, grade 3 constipation was associated with a higher MDS-UPDRS total score with β coefficient of 14.88 (p = 0.02). Conclusions Anosmia but not constipation was associated with cognitive impairment in PD patients. Nevertheless, severe constipation was associated with impaired olfaction and PD disease severity. We suggest that the propagation of α-synuclein from the olfactory route is distinct from the enteric nervous system, but the intercommunication between these two routes is complex.
Collapse
Affiliation(s)
- Ming-Zhi Sheng
- Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Ting-Chun Fang
- Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Yi-Huei Chen
- Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Ming-Hong Chang
- Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan
- Department of Neurology, School of Medicine, National Yang-Ming University, Taipei, Taiwan
- * E-mail:
| | - Chun-Pai Yang
- Department of Neurology, Kuang Tien General Hospital, Taichung, Taiwan
| | - Ching-Heng Lin
- Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
| |
Collapse
|
15
|
Abstract
This cohort study examines the clinical course and prognosis of patients with COVID-19–related anosmia for 1 year after diagnosis.
Collapse
Affiliation(s)
- Marion Renaud
- Otorhinolaryngology Department, University Hospitals of Strasbourg, Strasbourg, France
| | - Claire Thibault
- Otorhinolaryngology Department, University Hospitals of Strasbourg, Strasbourg, France
| | - Floriane Le Normand
- Otorhinolaryngology Department, University Hospitals of Strasbourg, Strasbourg, France
| | - Emily G. Mcdonald
- Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Benoît Gallix
- Institut Hospitalo-Universitaire-Strasbourg, Strasbourg, France
- Department of Radiology, McGill University, Montreal, Quebec, Canada
- Faculte de Medecine, Universite de Strasbourg, Strasbourg, France
| | - Christian Debry
- Otorhinolaryngology Department, University Hospitals of Strasbourg, Strasbourg, France
| | - Aina Venkatasamy
- Institut Hospitalo-Universitaire-Strasbourg, Strasbourg, France
- Streinth Laboratory (Stress Response and Innovative Therapies), Inserm UMR_S 1113, Interface Recherche Fondamental et Appliquee à la Cancerologie, Strasbourg, France
| |
Collapse
|
16
|
Moraschini V, Reis D, Sacco R, Calasans‐Maia MD. Prevalence of anosmia and ageusia symptoms among long-term effects of COVID-19. Oral Dis 2021; 28 Suppl 2:2533-2537. [PMID: 34002923 PMCID: PMC8242542 DOI: 10.1111/odi.13919] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 04/24/2021] [Accepted: 05/13/2021] [Indexed: 12/26/2022]
Affiliation(s)
- Vittorio Moraschini
- Department of PeriodontologySchool of DentistryVeiga de Almeida UniversityRio de JaneiroBrazil
| | - Daiana Reis
- Department of PeriodontologySchool of DentistryVeiga de Almeida UniversityRio de JaneiroBrazil
| | - Roberto Sacco
- Division of DentistryOral Surgery DepartmentSchool of Medical SciencesUniversity of ManchesterManchesterUK
| | | |
Collapse
|
17
|
Abstract
A survey was conducted through a web link on the students and staff of the Università degli Studi di Milano, Italy in the period 14-30 April 2020. It was anonymous at the source and included history of COVID-19-related questions (fever, headache, cold, cough, anosmia, gastrointestinal complaints and separately fever over 38.5°C) in the previous three weeks, and similar information on cohabitants. A total of 14 374 subjects were included. Overall, from 24 March to 30 April, 3138 subjects (21.8%) reported COVID-19-like symptoms, and 219 (1.5%) fever above 38.5°C; 217 subjects performed at least one swab. Of these, 46 were positive (21.3% of those performed, 0.3% of the total). The frequency of any symptom was similar in women and men, but fever above 38.5°C was lower in women (multivariate odds ratio (OR) = 0.65, 95% confidence interval, CI, 0.49-0.85). There was a strong association between symptoms in the respondent and in cohabitants: 64% of subjects with symptoms reported at least one cohabitant with symptoms, compared to 14% of asymptomatic subjects (OR = 11.4, 95% CI, 10.4-12.6). The lower risk of serious symptoms in women, and the strong intra-nucleus of cohabitation contagiousness are an indication that at least part of the symptoms was caused by a new pathogen - SARS-CoV-2. These data, therefore, suggest that the number of persons affected by COVID-19 was much greater in northern Italy than the number of recorded cases. This has implications for the prevention, management and mortality of other serious diseases, including cancer.
Collapse
Affiliation(s)
- Eva Negri
- Department of Biomedical and Clinical Sciences
| | - Carlo La Vecchia
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| |
Collapse
|
18
|
Petrocelli M, Cutrupi S, Salzano G, Maglitto F, Salzano FA, Lechien JR, Saussez S, Boscolo-Rizzo P, De Riu G, Vaira LA. Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study. J Laryngol Otol 2021; 135:436-441. [PMID: 33888166 PMCID: PMC8111201 DOI: 10.1017/s002221512100116x] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/15/2021] [Indexed: 02/06/2023]
Abstract
BACKGROUND The long-term recovery rate for coronavirus disease 2019 related chemosensory disturbances has not yet been clarified. METHODS Olfactory and gustatory functions were assessed with psychophysical tests in patients in the first seven days from coronavirus disease 2019 onset and one, two, three and six months after the first evaluation. RESULTS A total of 300 patients completed the study. The improvement in olfactory function was significant at the two-month follow up. At the end of the observation period, 27 per cent of the patients still experienced a persistent olfactory disturbance, including anosmia in 5 per cent of cases. As for taste, the improvement in the psychophysical scores was significant only between the baseline and the 30-day control. At the 6-month evaluation, 10 per cent of the patients presented with a persistent gustatory disturbance with an incidence of complete ageusia of 1 per cent. CONCLUSION Six months after the onset of coronavirus disease 2019, about 6 per cent of patients still had a severe persistent olfactory or gustatory disturbance.
Collapse
Affiliation(s)
- M Petrocelli
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Maxillofacial Surgery Operative Unit, Italy
| | - S Cutrupi
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Dentistry Operative Unit, Bellaria and Maggiore Hospital, AUSL of Bologna, Italy
| | - G Salzano
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Maxillofacial Surgery Unit, University Hospital of Naples Federico II, Italy
| | - F Maglitto
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Maxillofacial Surgery Unit, University Hospital of Naples Federico II, Italy
| | - F A Salzano
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Otolaryngology Operative Unit, Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitan, University of Salerno, Italy
| | - J R Lechien
- Covid-19 Task Force of the Young-Otolaryngologists of the International Federation of Oto-rhino-laryngological Societies, Paris, France
- Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons, Belgium
| | - S Saussez
- Covid-19 Task Force of the Young-Otolaryngologists of the International Federation of Oto-rhino-laryngological Societies, Paris, France
- Department of Human and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons, Belgium
| | - P Boscolo-Rizzo
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Department of Medicine, Surgery and Health Sciences, University of Trieste, Italy
| | - G De Riu
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Maxillofacial Surgery Operative Unit, University Hospital of Sassari, Italy
- Department of Medical, Surgical and Experimental Sciences, Italy
| | - L A Vaira
- Italian Research Group on Chemosensory Disorders in Covid-19 Patients, Italy
- Maxillofacial Surgery Operative Unit, University Hospital of Sassari, Italy
- Biomedical Science Department, Biomedical Science PhD School, University of Sassari, Italy
| |
Collapse
|
19
|
Nouchi A, Chastang J, Miyara M, Lejeune J, Soares A, Ibanez G, Saadoun D, Morélot-Panzini C, Similowski T, Amoura Z, Boddaert J, Caumes E, Bleibtreu A, Lorenzo A, Tubach F, Pourcher V. Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study. Eur J Clin Microbiol Infect Dis 2021; 40:691-697. [PMID: 33033955 PMCID: PMC7543958 DOI: 10.1007/s10096-020-04056-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 09/30/2020] [Indexed: 12/22/2022]
Abstract
Anecdotal evidence rapidly accumulated during March 2020 from sites around the world that sudden hyposmia and hypogeusia are significant symptoms associated with the SARS-CoV-2 pandemic. Our objective was to describe the prevalence of hyposmia and hypogeusia and compare it in hospitalized and non-hospitalized COVID-19 patients to evaluate an association of these symptoms with disease severity. We performed a cross-sectional survey during 5 consecutive days in March 2020, within a tertiary referral center, associated outpatient clinic, and two primary care outpatient facilities in Paris. All SARS-CoV-2-positive patients hospitalized during the study period and able to be interviewed (n = 198), hospital outpatients seen during the previous month (n = 129), and all COVID-19-highly suspect patients in two primary health centers (n = 63) were included. Hospitalized patients were significantly more often male (64 vs 40%) and older (66 vs 43 years old in median) and had significantly more comorbidities than outpatients. Hyposmia and hypogeusia were reported by 33% of patients and occurred significantly less frequently in hospitalized patients (12% and 13%, respectively) than in the health centers' outpatients (33% and 43%, respectively) and in the hospital outpatients (65% and 60%, respectively). Hyposmia and hypogeusia appeared more frequently after other COVID-19 symptoms. Patients with hyposmia and/or hypogeusia were significantly younger and had significantly less respiratory severity criteria than patients without these symptoms. Olfactory and gustatory dysfunction occurs frequently in COVID-19, especially in young, non-severe patients. These symptoms might be a useful tool for initial diagnostic work-up in patients with suspected COVID-19.
Collapse
Affiliation(s)
- Agathe Nouchi
- Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France.
- Département des Maladies Infectieuses et Tropicales, Groupe Hospitalier Universitaire APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
| | - Julie Chastang
- Département de Médecine Générale, Sorbonne Université, Paris, France
- INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Makoto Miyara
- INSERM UMR-S 1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Département d'Immunologie, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Julie Lejeune
- INSERM UMR-S-1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Unité de Recherche Clinique Pitié, CIC-1422, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - André Soares
- Département de Médecine Générale, Sorbonne Université, Paris, France
| | - Gladys Ibanez
- Département de Médecine Générale, Sorbonne Université, Paris, France
- INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - David Saadoun
- INSERM, UMR-S-959, Immunology-Immunopathology- Immunotherapy (I3), Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Capucine Morélot-Panzini
- INSERM, UMR-S-1158, Service de Pneumologie et Réanimation Médicale (Département R3S), Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Thomas Similowski
- INSERM, UMR-S-1158, Service de Pneumologie et Réanimation Médicale (Département R3S), Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Zahir Amoura
- Inserm UMR-S 1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Service de Médecine Interne 2, Groupe Hospitalier Universitaire APHP, Sorbonne-Université, site Pitié-Salpêtrière, Paris, France
| | - Jacques Boddaert
- Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
- INSERM UMR-S 1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Département d'Immunologie, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
- Service de Gériatrie, Groupe Hospitalier Universitaire APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Eric Caumes
- Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
- Département des Maladies Infectieuses et Tropicales, Groupe Hospitalier Universitaire APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
- INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Alexandre Bleibtreu
- Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
- Département des Maladies Infectieuses et Tropicales, Groupe Hospitalier Universitaire APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alain Lorenzo
- Département de Médecine Générale, Sorbonne Université, Paris, France
| | - Florence Tubach
- INSERM UMR-S-1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Unité de Recherche Clinique Pitié, CIC-1422, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| | - Valérie Pourcher
- Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
- Département des Maladies Infectieuses et Tropicales, Groupe Hospitalier Universitaire APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
- INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Groupe Hospitalier Universitaire APHP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France
| |
Collapse
|
20
|
Eskandar EN, Altschul DJ, de la Garza Ramos R, Cezayirli P, Unda SR, Benton J, Dardick J, Toma A, Patel N, Malaviya A, Flomenbaum D, Fernandez-Torres J, Lu J, Holland R, Burchi E, Zampolin R, Hsu K, McClelland A, Burns J, Erdfarb A, Malhotra R, Gong M, Semczuk P, Gursky J, Ferastraoaru V, Rosengard J, Antoniello D, Labovitz D, Esenwa C, Milstein M, Boro A, Mehler MF. Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19. Neurology 2021; 96:e1527-e1538. [PMID: 33443111 PMCID: PMC8032378 DOI: 10.1212/wnl.0000000000011356] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/24/2020] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is protean in its manifestations, affecting nearly every organ system. However, nervous system involvement and its effect on disease outcome are poorly characterized. The objective of this study was to determine whether neurologic syndromes are associated with increased risk of inpatient mortality. METHODS A total of 581 hospitalized patients with confirmed SARS-CoV-2 infection, neurologic involvement, and brain imaging were compared to hospitalized non-neurologic patients with coronavirus disease 2019 (COVID-19). Four patterns of neurologic manifestations were identified: acute stroke, new or recrudescent seizures, altered mentation with normal imaging, and neuro-COVID-19 complex. Factors present on admission were analyzed as potential predictors of in-hospital mortality, including sociodemographic variables, preexisting comorbidities, vital signs, laboratory values, and pattern of neurologic manifestations. Significant predictors were incorporated into a disease severity score. Patients with neurologic manifestations were matched with patients of the same age and disease severity to assess the risk of death. RESULTS A total of 4,711 patients with confirmed SARS-CoV-2 infection were admitted to one medical system in New York City during a 6-week period. Of these, 581 (12%) had neurologic issues of sufficient concern to warrant neuroimaging. These patients were compared to 1,743 non-neurologic patients with COVID-19 matched for age and disease severity admitted during the same period. Patients with altered mentation (n = 258, p = 0.04, odds ratio [OR] 1.39, confidence interval [CI] 1.04-1.86) or radiologically confirmed stroke (n = 55, p = 0.001, OR 3.1, CI 1.65-5.92) had a higher risk of mortality than age- and severity-matched controls. CONCLUSIONS The incidence of altered mentation or stroke on admission predicts a modest but significantly higher risk of in-hospital mortality independent of disease severity. While other biomarker factors also predict mortality, measures to identify and treat such patients may be important in reducing overall mortality of COVID-19.
Collapse
Affiliation(s)
- Emad Nader Eskandar
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - David J Altschul
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY.
| | - Rafael de la Garza Ramos
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Phillip Cezayirli
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Santiago R Unda
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Joshua Benton
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Joseph Dardick
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Aureliana Toma
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Nikunj Patel
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Avinash Malaviya
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - David Flomenbaum
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Jenelys Fernandez-Torres
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Jenny Lu
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Ryan Holland
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Elisabetta Burchi
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Richard Zampolin
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Kevin Hsu
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Andrew McClelland
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Judah Burns
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Amichai Erdfarb
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Rishi Malhotra
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Michelle Gong
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Peter Semczuk
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Jonathan Gursky
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Victor Ferastraoaru
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Jillian Rosengard
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Daniel Antoniello
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Daniel Labovitz
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Charles Esenwa
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Mark Milstein
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Alexis Boro
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| | - Mark F Mehler
- From the Departments of Neurological Surgery (E.N.E., D.J.A., R.d.l.G.R., P.C., S.R.U., J. Benton, J.D., A.T., J.F.-T., J.L., R.H., E.B.), Neurology (N.P., A. Malaviya, D.F., D.A., D.L., J.G., V.F., J.R., C.E., M.M., A.B., M.F.M.), Radiology (R.Z., K.H., A. McClelland, J. Burns, A.E.), and Critical Care Medicine (R.M., M.G.), Albert Einstein College of Medicine, Montefiore Medical Center (P.S., V.F., J.R.), Bronx, NY
| |
Collapse
|
21
|
Weiss JJ, Attuquayefio TN, White EB, Li F, Herz RS, White TL, Campbell M, Geng B, Datta R, Wyllie AL, Grubaugh ND, Casanovas-Massana A, Muenker MC, Moore AJ, Handoko R, Iwasaki A, Martinello RA, Ko AI, Small DM, Farhadian SF. Tracking smell loss to identify healthcare workers with SARS-CoV-2 infection. PLoS One 2021; 16:e0248025. [PMID: 33657167 PMCID: PMC7928484 DOI: 10.1371/journal.pone.0248025] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 02/18/2021] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION Healthcare workers (HCW) treating COVID-19 patients are at high risk for infection and may also spread infection through their contact with vulnerable patients. Smell loss has been associated with SARS-CoV-2 infection, but it is unknown whether monitoring for smell loss can be used to identify asymptomatic infection among high risk individuals. In this study we sought to determine if tracking smell sensitivity and loss using an at-home assessment could identify SARS-CoV-2 infection in HCW. METHODS AND FINDINGS We performed a prospective cohort study tracking 473 HCW across three months to determine if smell loss could predict SARS-CoV-2 infection in this high-risk group. HCW subjects completed a longitudinal, behavioral at-home assessment of olfaction with household items, as well as detailed symptom surveys that included a parosmia screening questionnaire, and real-time quantitative polymerase chain reaction testing to identify SARS-CoV-2 infection. Our main measures were the prevalence of smell loss in SARS-CoV-2-positive HCW versus SARS-CoV-2-negative HCW, and timing of smell loss relative to SARS-CoV-2 test positivity. SARS-CoV-2 was identified in 17 (3.6%) of 473 HCW. HCW with SARS-CoV-2 infection were more likely to report smell loss than SARS-CoV-2-negative HCW on both the at-home assessment and the screening questionnaire (9/17, 53% vs 105/456, 23%, P < .01). 6/9 (67%) of SARS-CoV-2-positive HCW reporting smell loss reported smell loss prior to having a positive SARS-CoV-2 test, and smell loss was reported a median of two days before testing positive. Neurological symptoms were reported more frequently among SARS-CoV-2-positive HCW who reported smell loss compared to those without smell loss (9/9, 100% vs 3/8, 38%, P < .01). CONCLUSIONS In this prospective study of HCW, self-reported changes in smell using two different measures were predictive of SARS-CoV-2 infection. Smell loss frequently preceded a positive test and was associated with neurological symptoms.
Collapse
Affiliation(s)
- Julian J. Weiss
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Tuki N. Attuquayefio
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Elizabeth B. White
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Fangyong Li
- Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Rachel S. Herz
- Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
| | - Theresa L. White
- Department of Psychology, Le Moyne College, Syracuse, New York, United States of America
- SUNY Upstate Medical University, Syracuse, New York, United States of America
| | - Melissa Campbell
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
- Center for Outcomes Research and Evaluation, Yale-New Haven Health, New Haven, Connecticut, United States of America
| | - Bertie Geng
- Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Rupak Datta
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Anne L. Wyllie
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Nathan D. Grubaugh
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Arnau Casanovas-Massana
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - M. Catherine Muenker
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Adam J. Moore
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Ryan Handoko
- Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Akiko Iwasaki
- Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America
- Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America
| | - Richard A. Martinello
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Infection Prevention, Yale-New Haven Health, New Haven, Connecticut, United States of America
| | - Albert I. Ko
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Dana M. Small
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Psychology, Yale University, New Haven, Connecticut, United States of America
| | - Shelli F. Farhadian
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, United States of America
- Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America
| | | |
Collapse
|
22
|
Güemes A, Ray S, Aboumerhi K, Desjardins MR, Kvit A, Corrigan AE, Fries B, Shields T, Stevens RD, Curriero FC, Etienne-Cummings R. A syndromic surveillance tool to detect anomalous clusters of COVID-19 symptoms in the United States. Sci Rep 2021; 11:4660. [PMID: 33633250 DOI: 10.1101/2020.08.18.20177295] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 02/12/2021] [Indexed: 05/25/2023] Open
Abstract
Coronavirus SARS-COV-2 infections continue to spread across the world, yet effective large-scale disease detection and prediction remain limited. COVID Control: A Johns Hopkins University Study, is a novel syndromic surveillance approach, which collects body temperature and COVID-like illness (CLI) symptoms across the US using a smartphone app and applies spatio-temporal clustering techniques and cross-correlation analysis to create maps of abnormal symptomatology incidence that are made publicly available. The results of the cross-correlation analysis identify optimal temporal lags between symptoms and a range of COVID-19 outcomes, with new taste/smell loss showing the highest correlations. We also identified temporal clusters of change in taste/smell entries and confirmed COVID-19 incidence in Baltimore City and County. Further, we utilized an extended simulated dataset to showcase our analytics in Maryland. The resulting clusters can serve as indicators of emerging COVID-19 outbreaks, and support syndromic surveillance as an early warning system for disease prevention and control.
Collapse
Affiliation(s)
- Amparo Güemes
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA.
| | - Soumyajit Ray
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| | - Khaled Aboumerhi
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| | - Michael R Desjardins
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Anton Kvit
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Anne E Corrigan
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Brendan Fries
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Timothy Shields
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Robert D Stevens
- Department of Anesthesiology and Critical Care Medicine, Neurology, Neurosurgery and Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
| | - Frank C Curriero
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Ralph Etienne-Cummings
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| |
Collapse
|
23
|
Khedr EM, Abo-Elfetoh N, Deaf E, Hassan HM, Amin MT, Soliman RK, Attia AA, Zarzour AA, Zain M, Mohamed-Hussein A, Hashem MK, Hassany SM, Aly A, Shoyb A, Saber M. Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals. Neuroepidemiology 2021; 55:109-118. [PMID: 33631765 PMCID: PMC8018217 DOI: 10.1159/000513647] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 12/04/2020] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND COVID-19 can be accompanied by acute neurological complications of both central and peripheral nervous systems (CNS and PNS). In this study, we estimate the frequency of such complications among hospital inpatients with COVID-19 in Assiut and Aswan university hospitals. MATERIALS AND METHODS We screened all patients with suspected COVID-19 admitted from 1 June to 10 August 2020 to the university hospitals of Assiut and Aswan in Upper Egypt. Clinical and laboratory tests, CT/MRI of the chest and brain, and neurophysiology study were performed for each patient if indicated. RESULTS 439 patients had confirmed/probable COVID-19; neurological manifestations occurred in 222. Of these, 117 had acute neurological disease and the remainder had nonspecific neuropsychiatric symptoms such as headache, vertigo, and depression. The CNS was affected in 75 patients: 55 had stroke and the others had convulsions (5), encephalitis (6), hypoxic encephalopathy (4), cord myelopathy (2), relapse of multiple sclerosis (2), and meningoencephalitis (1). The PNS was affected in 42 patients: the majority had anosmia and ageusia (31) and the others had Guillain-Barré syndrome (4), peripheral neuropathy (3), myasthenia gravis (MG, 2), or myositis (2). Fever, respiratory symptoms, and headache were the most common general symptoms. Hypertension, diabetes mellitus, and ischemic heart disease were the most common comorbidities in patients with CNS affection. CONCLUSION In COVID-19, both the CNS and PNS are affected. Stroke was the most common complication for CNS, and anosmia and/or ageusia were common for PNS diseases. However, there were 6 cases of encephalitis, 2 cases of spinal cord myelopathy, 2 cases of MG, and 2 cases of myositis.
Collapse
Affiliation(s)
- Eman M Khedr
- Department of Neuropsychiatry, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt,
| | - Noha Abo-Elfetoh
- Department of Neuropsychiatry, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | - Enas Deaf
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt
| | - Hebatallah M Hassan
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt
| | - Mariam T Amin
- Department of Public Health and Community Medicine, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | - Radwa K Soliman
- Department of Radiology, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | - Alaa A Attia
- Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Assiut, Egypt
| | - Amro A Zarzour
- Department of Anesthesia and Intensive Care, Faculty of Medicine, Assiut University, Assiut, Egypt
| | - Mohamed Zain
- Department of Internal Medicine, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | | | - Maiada K Hashem
- Department of Chest, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | - Sahar M Hassany
- Department of Tropical Medicine and GIT, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt
| | - Ahmed Aly
- Department of Neurosurgery, Assiut University Hospital, Faculty of Medicine, Aswan, Egypt
| | - Ahmed Shoyb
- Department of Neuropsychiatry, Assiut University Hospital, Faculty of Medicine, Aswan, Egypt
| | - Mostafa Saber
- Department of Neuropsychiatry, Assiut University Hospital, Faculty of Medicine, Aswan, Egypt
| |
Collapse
|
24
|
Güemes A, Ray S, Aboumerhi K, Desjardins MR, Kvit A, Corrigan AE, Fries B, Shields T, Stevens RD, Curriero FC, Etienne-Cummings R. A syndromic surveillance tool to detect anomalous clusters of COVID-19 symptoms in the United States. Sci Rep 2021; 11:4660. [PMID: 33633250 PMCID: PMC7907397 DOI: 10.1038/s41598-021-84145-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 02/12/2021] [Indexed: 11/13/2022] Open
Abstract
Coronavirus SARS-COV-2 infections continue to spread across the world, yet effective large-scale disease detection and prediction remain limited. COVID Control: A Johns Hopkins University Study, is a novel syndromic surveillance approach, which collects body temperature and COVID-like illness (CLI) symptoms across the US using a smartphone app and applies spatio-temporal clustering techniques and cross-correlation analysis to create maps of abnormal symptomatology incidence that are made publicly available. The results of the cross-correlation analysis identify optimal temporal lags between symptoms and a range of COVID-19 outcomes, with new taste/smell loss showing the highest correlations. We also identified temporal clusters of change in taste/smell entries and confirmed COVID-19 incidence in Baltimore City and County. Further, we utilized an extended simulated dataset to showcase our analytics in Maryland. The resulting clusters can serve as indicators of emerging COVID-19 outbreaks, and support syndromic surveillance as an early warning system for disease prevention and control.
Collapse
Affiliation(s)
- Amparo Güemes
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA.
| | - Soumyajit Ray
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| | - Khaled Aboumerhi
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| | - Michael R Desjardins
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Anton Kvit
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Anne E Corrigan
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Brendan Fries
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Timothy Shields
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Robert D Stevens
- Department of Anesthesiology and Critical Care Medicine, Neurology, Neurosurgery and Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
| | - Frank C Curriero
- Department of Epidemiology, Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
| | - Ralph Etienne-Cummings
- Department of Electrical and Computer Engineering, Johns Hopkins Whiting School of Engineering, The Johns Hopkins University, 3400 N. Charles Street, 105 Barton Hall, Baltimore, MD, 21218, USA
| |
Collapse
|
25
|
Aziz M, Goyal H, Haghbin H, Lee-Smith WM, Gajendran M, Perisetti A. The Association of "Loss of Smell" to COVID-19: A Systematic Review and Meta-Analysis. Am J Med Sci 2021; 361:216-225. [PMID: 33349441 PMCID: PMC7604015 DOI: 10.1016/j.amjms.2020.09.017] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 08/19/2020] [Accepted: 09/28/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND The presence of olfactory dysfunction or "loss of smell" has been reported as an atypical symptom in patients with coronavirus disease 2019 (COVID-19). We performed a systematic review and meta-analysis of the available literature to evaluate the prevalence of "loss of smell" in COVID-19 as well as its utility for prognosticating the disease severity. METHODS An exhaustive search of the PubMed/Medline, Embase, Web of Science, Cochrane Library, LitCovid NIH, and WHO COVID-19 database was conducted through August 6th, 2020. All studies reporting the prevalence of "loss of smell" (anosmia and/or hyposmia/microsmia) in laboratory-confirmed COVID-19 patients were included. Pooled prevalence for cases (positive COVID-19 through reverse transcriptase (RT-PCR) and/or serology IgG/IgM) and controls (negative RT-PCR and/or serology) was compared, and the odds ratio (OR), 95% confidence interval (CI) and the p-value were calculated. A p-value of <0.05 was considered statistically significant. RESULTS A total of 51 studies with 11074 confirmed COVID-19 patients were included. Of these, 21 studies used a control group with 3425 patients. The symptom of "loss of smell" (OR: 14.7, CI: 8.9-24.3) was significantly higher in the COVID-19 group when compared to the control group. Seven studies comparing severe COVID-19 patients with- and without "loss of smell" demonstrated favorable prognosis for patients with "loss of smell" (OR: 0.36, CI 0.27-0.48). CONCLUSIONS Olfactory dysfunction or "loss of smell" is a prevalent symptom in COVID-19 patients. Moreover, COVID-19 patients with "loss of smell" appear to have a milder course of the disease.
Collapse
Affiliation(s)
- Muhammad Aziz
- Department of Internal Medicine, University of Toledo, Toledo, Ohio
| | - Hemant Goyal
- The Wright Center for Graduate Medical Education, Scranton, Pennsylvania.
| | - Hossein Haghbin
- Department of Internal Medicine, University of Toledo, Toledo, Ohio
| | | | - Mahesh Gajendran
- Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas
| | - Abhilash Perisetti
- Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| |
Collapse
|
26
|
Mubaraki AA, Alrbaiai GT, Sibyani AK, Alhulayfi RM, Alzaidi RS, Almalki HS. Prevalence of anosmia among COVID-19 patients in Taif City, Kingdom of Saudi Arabia. Saudi Med J 2021; 42:38-43. [PMID: 33399169 PMCID: PMC7989313 DOI: 10.15537/smj.2021.1.25588] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Objectives: To assess the prevalence of anosmia in coronavirus-19 (COVID-19) patients. Coronavirus-19-related anosmia and hyposmia is a new emerging concept in the medical literature. Methods: A retrospective study on COVID-19 patients with anosmia and hyposmia was performed during the period between May-July, 2020. The inclusion criteria were all clinically stable COVID-19 patients >15 years old with positive reverse transcription-polymerase chain reaction (RT-PCR). Patients who refused to participate or leave incomplete questions were excluded. In this study, we investigated 1022 patients who met our criteria. Results: Olfactory dysfunction (OD) was reported by 53% of our COVID-19 patients, of which 32.7% were anosmic and 20.3% were hyposmic. Other neurological symptoms included ageusia (51.4%), fatigue (63%), myalgia (59.2%), and headache (50.9%), all of which showed significant association with OD. In addition, anosmia had a significant association with young age and female gender. However, there was no association between OD and pre-existing neurological disease. Conclusion: Half of our COVID-19 patients presented OD (anosmia/hyposmia), which often associated with ageusia and many neurological symptoms.
Collapse
Affiliation(s)
- Adnan A Mubaraki
- Department of Medicine, Taif University, Taif, Kingdom of Saudi Arabia. E-mail.
| | | | | | | | | | | |
Collapse
|
27
|
Spadera L, Viola P, Pisani D, Scarpa A, Malanga D, Sorrentino G, Madini E, Laria C, Aragona T, Leopardi G, Maggiore G, Ciriolo M, Boccuto L, Pizzolato R, Abenavoli L, Cassandro C, Ralli M, Cassandro E, Chiarella G. Sudden olfactory loss as an early marker of COVID-19: a nationwide Italian survey. Eur Arch Otorhinolaryngol 2021; 278:247-255. [PMID: 32749606 PMCID: PMC7399588 DOI: 10.1007/s00405-020-06252-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Accepted: 07/27/2020] [Indexed: 01/29/2023]
Abstract
PURPOSE The presence of many asymptomatic COVID-19 cases may increase the risks of disease dissemination, mainly for physicians. There are numerous reports on the frequent findings of sudden anosmia or hyposmia, before or at the same time of the typical COVID-19 symptoms onset. The aim of this study was to verify the association of olfactory impairment and COVID-19, providing a basis for subsequent research in the field of COVID-19 clinical heterogeneity. METHODS We developed a 15-item online questionnaire on "Sudden Olfactory Loss (SOL) and COVID-19" that was administered during March 2020 to Italian general practitioners registered to a social media group. RESULTS One hundred and eighty responses were received. SOL was identified as a significant sign of infection in COVID-19 patients, mainly aged between 30 and 40 years, even in the absence of other symptoms. SOL was present as an initial symptom in 46.7% of subjects, and in 16.7%, it was the only symptom. Among the COVID-19 confirmed cases, SOL occurred as the only symptom in 19.2% of patients. CONCLUSION SOL could represent a possible early symptom in otherwise asymptomatic COVID-19 subjects. Subjects affected by SOL should be considered as potential COVID-19 cases. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- Lucrezia Spadera
- Otolaryngology, San Leonardo Hospital, Castellammare di Stabia, Naples, Italy
| | - Pasquale Viola
- Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy
| | - Davide Pisani
- Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy
| | - Alfonso Scarpa
- Department of Medicine and Surgery, University of Salerno, Salerno, Italy
| | - Donatella Malanga
- Laboratory of Molecular Oncology, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
- Interdepartmental Center of Services (CIS), University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Gerardo Sorrentino
- Otolaryngology, San Leonardo Hospital, Castellammare di Stabia, Naples, Italy
| | | | - Carla Laria
- Unit of Audiology, Department of Neurosciences, Reproductives and Odontostomatologic Sciences, University of Naples “Federico II”, Naples, Italy
| | | | | | | | - Marco Ciriolo
- Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy
| | - Luigi Boccuto
- Greenwood Genetic Center, Greenwood, SC USA
- Clemson University, Clemson, SC USA
| | - Raffaella Pizzolato
- Department of Neurology, University of Massachusetts, Medical School, Worcester, MA USA
| | - Ludovico Abenavoli
- Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
| | | | - Massimo Ralli
- Department of Sense Organs, Sapienza University of Rome, Rome, Italy
| | - Ettore Cassandro
- Department of Medicine and Surgery, University of Salerno, Salerno, Italy
| | - Giuseppe Chiarella
- Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy
| |
Collapse
|
28
|
Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, Joseph PV, Reed DR. Objective Sensory Testing Methods Reveal a Higher Prevalence of Olfactory Loss in COVID-19-Positive Patients Compared to Subjective Methods: A Systematic Review and Meta-Analysis. Chem Senses 2020; 45:865-874. [PMID: 33245136 PMCID: PMC7543258 DOI: 10.1093/chemse/bjaa064] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Indexed: 11/13/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has currently infected over 6.5 million people worldwide. In response to the pandemic, numerous studies have tried to identify the causes and symptoms of the disease. Emerging evidence supports recently acquired anosmia (complete loss of smell) and hyposmia (partial loss of smell) as symptoms of COVID-19, but studies of olfactory dysfunction show a wide range of prevalence from 5% to 98%. We undertook a search of Pubmed/Medline and Google Scholar with the keywords "COVID-19," "smell," and/or "olfaction." We included any study that quantified smell loss (anosmia and hyposmia) as a symptom of COVID-19. Studies were grouped and compared based on the type of method used to measure smell loss-subjective measures, such as self-reported smell loss, versus objective measures using rated stimuli-to determine if prevalence differed by method type. For each study, 95% confidence intervals (CIs) were calculated from point estimates of olfactory disturbances. We identified 34 articles quantifying anosmia as a symptom of COVID-19 (6 objective and 28 subjective), collected from cases identified from January 16 to April 30, 2020. The pooled prevalence estimate of smell loss was 77% when assessed through objective measurements (95% CI of 61.4-89.2%) and 44% with subjective measurements (95% CI of 32.2-57.0%). Objective measures are a more sensitive method to identify smell loss as a result of infection with SARS-CoV-2; the use of subjective measures, while expedient during the early stages of the pandemic, underestimates the true prevalence of smell loss.
Collapse
Affiliation(s)
| | - Vicente A Ramirez
- Monell Chemical Senses Center, Philadelphia, PA
- Department of Public Health, University of California Merced, Merced, CA
| | | | | | | | - Cailu Lin
- Monell Chemical Senses Center, Philadelphia, PA
| | - Paule V Joseph
- Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA
- Division of Intramural Research, National Institute of Nursing Research & National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA
| | | |
Collapse
|
29
|
Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, Acors S, Kouphou N, Neil SJD, Tedder RS, Matos PM, Poulton K, Lista MJ, Dickenson RE, Sertkaya H, Maguire TJA, Scourfield EJ, Bowyer RCE, Hart D, O'Byrne A, Steel KJA, Hemmings O, Rosadas C, McClure MO, Capedevilla-Pujol J, Wolf J, Ourselin S, Brown MA, Malim MH, Spector T, Steves CJ. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect 2020; 81:931-936. [PMID: 33068628 PMCID: PMC7557299 DOI: 10.1016/j.jinf.2020.10.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 10/11/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. METHODS We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. FINDINGS We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. INTERPRETATION Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. FUNDING NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
Collapse
Affiliation(s)
- Philippa M Wells
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK
| | - Katie J Doores
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Simon Couvreur
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK
| | - Rocio Martinez Nunez
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Jeffrey Seow
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Carl Graham
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Sam Acors
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Neophytos Kouphou
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Stuart J D Neil
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | | | - Pedro M Matos
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Kate Poulton
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Maria Jose Lista
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Ruth E Dickenson
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Helin Sertkaya
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Thomas J A Maguire
- Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Edward J Scourfield
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Ruth C E Bowyer
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK
| | - Deborah Hart
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK
| | - Aoife O'Byrne
- Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Kathryn J A Steel
- Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Oliver Hemmings
- Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK
| | | | - Myra O McClure
- Department of Infectious Disease, Imperial College London, UK
| | | | | | - Sebastien Ourselin
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
| | - Matthew A Brown
- Department of Medical & Molecular Genetics, Guy's and St Thomas' Hospital NHS Trust and King's College London NIHR Biomedical Research Centre, London, UK
| | - Michael H Malim
- Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK
| | - Tim Spector
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK
| | - Claire J Steves
- Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
| |
Collapse
|
30
|
Asseo K, Fierro F, Slavutsky Y, Frasnelli J, Niv MY. Tracking COVID-19 using taste and smell loss Google searches is not a reliable strategy. Sci Rep 2020; 10:20527. [PMID: 33239650 PMCID: PMC7689487 DOI: 10.1038/s41598-020-77316-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Accepted: 10/29/2020] [Indexed: 02/06/2023] Open
Abstract
Web search tools are widely used by the general public to obtain health-related information, and analysis of search data is often suggested for public health monitoring. We analyzed popularity of searches related to smell loss and taste loss, recently listed as symptoms of COVID-19. Searches on sight loss and hearing loss, which are not considered as COVID-19 symptoms, were used as control. Google Trends results per region in Italy or state in the US were compared to COVID-19 incidence in the corresponding geographical areas. The COVID-19 incidence did not correlate with searches for non-symptoms, but in some weeks had high correlation with taste and smell loss searches, which also correlated with each other. Correlation of the sensory symptoms with new COVID-19 cases for each country as a whole was high at some time points, but decreased (Italy) or dramatically fluctuated over time (US). Smell loss searches correlated with the incidence of media reports in the US. Our results show that popularity of symptom searches is not reliable for pandemic monitoring. Awareness of this limitation is important during the COVID-19 pandemic, which continues to spread and to exhibit new clinical manifestations, and for potential future health threats.
Collapse
Affiliation(s)
- Kim Asseo
- The Institute of Biochemistry, Food Science and Nutrition, The Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel
| | - Fabrizio Fierro
- The Institute of Biochemistry, Food Science and Nutrition, The Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel
| | - Yuli Slavutsky
- Department of Statistics and Data Science, The Hebrew University of Jerusalem, Rehovot, Israel
| | - Johannes Frasnelli
- Department of Anatomy, University of Québec in Trois-Rivières, Trois-Rivières, QC, Canada
| | - Masha Y Niv
- The Institute of Biochemistry, Food Science and Nutrition, The Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.
| |
Collapse
|